We conducted an updated literature review to summarize and discuss the potential therapeutic targets to be employed against PAH, including PDGF/PDGFR signaling, the PI3K/AKT pathway, regulators in glycolytic metabolism, HSP90, HMGB1, BET proteins, and p53. The gene discussed is PDGFRB; the disease is pulmonary arterial hypertension.